Document is current
Any future updates will be listed below
-
Authors
van Boven, Job FM
van Raaij, Joost J
van der Galiën, Ruben
Postma, Maarten J
van der Molen, Thys
Dekhuijzen, PN Richard
Vegter, Stefan
- License Information
-
More Information
Article History
Received: 28 September 2013
Revised: 23 June 2014
Accepted: 12 August 2014
First Online: 2 October 2014
Competing interests
: TvdM has received research grants from AstraZeneca, GlaxoSmithKline, Nycomed, MSD, Almirall, consultancy fees for advisory boards from AstraZeneca, Nycomed, MSD, Novartis, Almirall and speaker fees from AstraZeneca, GlaxoSmithKline, Nycomed, Novartis and MSD. PNRD has received reimbursements for attending symposia, fees for speaking, organising educational events, funds for research or fees for consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi, MSD, Mundipharma, Novartis, Takeda, Almirall and Teva. MJP has received grants, honoraria and travel stipends from various pharmaceutical companies including GlaxoSmithKline. The remaining authors declare no conflict of interest.
